Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.

British journal of haematology - 1 Apr 2017

Gao Rui, Liang Jin-Hua, Wang Li, Zhu Hua-Yuan, Wu Wei, Wu Jia-Zhu, Xia Yi, Cao Lei, Fan Lei, Yang Tao, Li Jian-Yong, Xu Wei

Abstract excerpt

The aim of this study was to evaluate the prognostic effect of low triiodothyronine (T3) syndrome on patients with diffuse large B cell lymphoma (DLBCL). A hundred and eighty-eight patients with detailed thyroid hormone levels at diagnosis of DLBCL were enrolled. Low T3 syndrome was defined as a low serum free T3 (FT3) level with low or normal serum free tetraiodothyronine (FT4) and thyroid stimulating hormone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm Staging

Share to Prognosis

Share to Survival Analysis

Share to Treatment Outcome

Source

Identifiers

PMID: 28146267
DOI: 10.1111/bjh.14528

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.PMID 28146267Read ↗

Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.Semantic proximity Read ↗

Clinical features and immunophenotypes of double-hit diffuse large B-cell lymphomaSemantic proximity Read ↗

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read ↗

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.Semantic proximity Read ↗

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Semantic proximity Read ↗

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.Semantic proximity Read ↗

T-cell lymphoma patient harboring BCL11B mutations had favorable overall survival.Semantic proximity Read ↗

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma.Semantic proximity Read ↗

A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations.Semantic proximity Read ↗

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.